3 Healthcare Stocks That Are Too Cheap to Ignore

Canadians should look to snatch up cheap healthcare stocks like Bausch Health Companies Inc. (TSX:BHC) before the new year.

| More on:
A doctor takes a patient's blood pressure in a clinical office.

Source: Getty Images

The S&P/TSX Composite Index climbed 106 points on Tuesday, December 20. However, the S&P/TSX Capped Health Care Index fell by 2.62%, which was the sharpest loss among the top sectors on the TSX. That is largely due to reeling cannabis stocks that have dragged the index for years. Today, I want to zero in on three healthcare stocks that look cheap in late December. Let’s dive in.

This exciting healthcare stock looks like a strong buy right now

Andlauer Healthcare (TSX:AND) is a Toronto-based supply chain management company that provides a platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector in Canada and the United States. That means this company offers Canadian investors exposure to the burgeoning healthcare and supply management spaces. Shares of this healthcare stock have dropped 11% in 2022 as of close on December 20. That has pushed the stock into negative territory in the year-over-year period.

This company released its third quarter (Q3) fiscal 2022 results on November 8. It delivered revenue growth of 58% to $164 million. Meanwhile, it posted net income of $19.0 million, or $0.44 per share — up from $12.2 million, or $0.31 per share, in the third quarter of fiscal 2021. Andlauer was bolstered by recent acquisitions in its healthcare logistics and specialized transportation segments.

Shares of this cheap healthcare stock possess a favourable price-to-earnings (P/E) ratio of 19. Moreover, it offers a quarterly dividend of $0.07 per share. That represents a modest 0.5% yield.

Here’s a very promising stock that looks dirt cheap in late December

Bausch Health (TSX:BHC) is another cheap healthcare stock that I’d look to snatch up in the final days of 2022. This Laval-based company that develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. Its shares have plunged 73% in the year-to-date period.

In Q3 2022, Bausch Health saw revenues drop 3% year over year to $2.04 billion. Meanwhile, it posted non-GAAP adjusted net income of $291 million compared to $420 million in the previous year. Bausch reported adjusted net income of $768 million in the first nine months of fiscal 2022 — down from $1.14 billion in the year-to-date period in fiscal 2021.

This healthcare stock last had an attractive P/E ratio of 9.7. It is trading in more favourable value territory compared to its industry peers. I’m looking to pick up Bausch for cheap before the new year.

One more undervalued healthcare stock that also boasts a solid dividend

Medical Facilities (TSX:DR) is the third healthcare stock I’d look to snatch up before we kick off 2023. This Toronto-based company owns and operates specialty surgical hospitals and an ambulatory surgery centre in the United States. Shares of Medical Facilities have declined 12% in 2022. However, the stock is up 2.8% month over month.

The company unveiled its Q3 2022 earnings on November 10. Total revenue and other income grew 3.2% to $102 million. Meanwhile, surgical case volumes rose 3% and facility service revenue posted 6% growth. Shares of this healthcare stock possess a solid P/E ratio of 23, which currently outpaces its industry peers. Better yet, this cheap healthcare stock offers a quarterly dividend of $0.081 per share, which represents a 4% yield.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any stocks mentioned.

More on Investing

calculate and analyze stock
Dividend Stocks

TFSA: Invest $20,000 and Get $867/Year Without Lifting a Finger

Compound passive income by investing tax-free in your TFSA. Check out this mini-portfolio that could turn $20K into $867/year in…

Read more »

A bull and bear face off.
Energy Stocks

2 Top TSX Energy Stocks to Buy as Crude Oil Is Set to Soar Higher

TSX energy stocks might keep topping charts in 2023 as well.

Read more »

money cash dividends

Sitting on Cash? These 2 Stocks Are Great Buys

The best stocks to buy now include Fiera Capital (TSX:FSZ).

Read more »

Young woman sat at laptop by a window
Bank Stocks

Could BMO Stock Be a Big Winner in 2023?

Long-term investors should take a closer look at BMO stock as a potential core holding, especially on dips.

Read more »

retirees and finances
Dividend Stocks

How to Create a Million-Dollar TFSA in Two Decades

Your TFSA could create riches you didn't know were possible, but only if you commit again and again to your…

Read more »

edit U-turn

2 Bounce-Back Plays for Young TFSA Investors

Cineplex (TSX:CGX) and Corus Entertainment (TSX:CJR.B) are deeply discounted stocks to entertain your TFSA.

Read more »

Target. Stand out from the crowd

3 Growth Stocks I’d Buy More of if They Took a Dip

Tech stocks like Quarterhill (TSX:QTRH) may have hit a bottom recently.

Read more »

A plant grows from coins.
Dividend Stocks

TFSA Top Stocks: 2 Cheap Dividend-Payers to Buy Before January Ends

TFSA investors can appreciate dividend-paying stocks like Barrick Gold at these modest valuations.

Read more »